$TTRX

Turn Therapeutics Inc.

Turn Therapeutics develops topical treatments for inflammatory skin disease, primarily for moderate-to-severe eczema and onychomycosis, or fungal nail infection. Its lead candidate, GX-03, is a non-systemic topical immunomodulator being studied in a clinical trial for eczema and is also being advanced for onychomycosis. The company has FDA-cleared medical device products using the same base formulation, including K160872 for wound management, K171191 for dermatitis management and K183681, an antimicrobial gauze licensed to Medline. Turn also conducts exploratory research on a thermostable intranasal vaccine platform. Turn’s business model includes licensing and selling medical device products through commercial partners, while focusing internal efforts on drug development. It also collaborates with partners on product development, manufacturing and commercialization, contributing its formulation expertise and intellectual property. Turn Therapeutics is headquartered in Westlake Village, California.

No enriched coverage for $TTRX in the last 7 days.

No SEC Form 4 filings for $TTRX in the last 30 days.

See all $TTRX insider activity →
Med

Turn Therapeutics Updates Investors on GX-03 Pipeline and Q1 2027 Atopic Dermatitis Readout

Turn Therapeutics (TTRX) updated investors on its GX-03 pipeline, including a Phase 2 trial for atopic dermatitis with results expected in Q1 2027, a Phase 2a trial for hidradenitis suppurativa planned for Q1 2027, and a Phase 3-ready onychomycosis treatment. The company reported $10.4M in cash as of September 30, 2026, with a runway into Q3 2027, and holds 17 issued patents.

Turn Therapeutics Reports Q3 2026 Net Loss of $6.2 Million

Turn Therapeutics (TTRX) reported a Q3 2026 net loss of $6.2M, or $0.21 per share, with $10.4M in cash. It expects funds to last until Q3 2027. The company reported progress in its atopic dermatitis program and plans to start a hidradenitis suppurativa trial in early 2027. GX-03 showed positive results in a Stage 1 atopic dermatitis trial, with 59.3% of patients achieving clear or almost clear skin after four weeks.

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results Completed GX-03 Stage 1/Phase 2a Trial: 59.3% of GX-03 Patients Achieved Clear or Almost Clear Skin After Four Weeks, Compared with 30.4% Receiving Vehicle Larger Phase 2b A

TTRX sentiment & insider activity

Recent TTRX coverage spans financial news, earnings and technology.

What's driving TTRX

AlphAI scores every news story that mentions TTRX with an AI model for sentiment and relevance, and aggregates insider trades from Turn Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TTRX

Score

Turn Therapeutics Updates Investors on GX-03 Pipeline and Q1 2027 Atopic Dermatitis Readout

Turn Therapeutics (TTRX) updated investors on its GX-03 pipeline, including a Phase 2 trial for atopic dermatitis with results expected in Q1 2027, a Phase 2a trial for hidradenitis suppurativa planned for Q1 2027, and a Phase 3-ready onychomycosis treatment. The company reported $10.4M in cash as of September 30, 2026, with a runway into Q3 2027, and holds 17 issued patents.

Turn Therapeutics Reports Q3 2026 Net Loss of $6.2 Million

Turn Therapeutics (TTRX) reported a Q3 2026 net loss of $6.2M, or $0.21 per share, with $10.4M in cash. It expects funds to last until Q3 2027. The company reported progress in its atopic dermatitis program and plans to start a hidradenitis suppurativa trial in early 2027. GX-03 showed positive results in a Stage 1 atopic dermatitis trial, with 59.3% of patients achieving clear or almost clear skin after four weeks.

$TTRXMedEarnings

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results Completed GX-03 Stage 1/Phase 2a Trial: 59.3% of GX-03 Patients Achieved Clear or Almost Clear Skin After Four Weeks, Compared with 30.4% Receiving Vehicle Larger Phase 2b A

WBB Securities upgrades Turn Therapeutics stock rating to hold

WBB Securities upgraded Turn Therapeutics (TTRX) to Hold from Sell, setting a $10.00 price target. The stock has fallen from $16.45 but is up over 200% in six months. WBB expects Phase 2 trial results in 2026, but sees challenges for small-cap life science firms. Lucid Capital Markets initiated coverage with a Buy rating and $24.00 target, citing GX-03's potential.

Turn updates investor presentation; Phase 2 AD topline due Q1 2027, $10.3M cash runways into Q3 2027

Turn Therapeutics updated its investor presentation, highlighting GX-03 clinical progress and a $10.3M cash balance as of June 30, 2026. The company expects Phase 2 topline results for atopic dermatitis in Q1 2027 and has a cash runway into Q3 2027. Key milestones include an FDA meeting in Q4 2026 and Phase 3 initiations in 2027. The presentation also details safety and efficacy signals, financials, and IP status.

$TTRXLowOffering· 579.66K · closed

Turn Therapeutics Inc. (TTRX): Unregistered Sales of Equity Securities

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed, on October 8, 2025, Turn Therapeutics Inc. (the “Company”) issued to GEM Yield Bahamas Limited a warrant (the “Warrant”) to purchase 1,192,207 shares of the Company’s common stock, par value $0.0001 per s

$TTRXMedEarnings

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Low

Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Turn Therapeutics stock rises on expanded dermatitis trial By Investing.com

Turn Therapeutics (TTRX) shares rose 3.8% premarket after expanding its GX-03 Phase 2 atopic dermatitis trial to a broader EASI severity population. The company completed an interim analysis and said efficacy was seen in mild-to-moderate patients (EASI 1.1–7.0), with 71.4% vs 33.3% vehicle achieving Week 4 vIGA-AD success. Final design targets ~120–135 patients; no treatment-related serious AEs reported.

Related tickers